GPCR-Hippo Signaling in Cancer

Cells. 2019 May 8;8(5):426. doi: 10.3390/cells8050426.

Abstract

The Hippo signaling pathway is involved in tissue size regulation and tumorigenesis. Genetic deletion or aberrant expression of some Hippo pathway genes lead to enhanced cell proliferation, tumorigenesis, and cancer metastasis. Recently, multiple studies have identified a wide range of upstream regulators of the Hippo pathway, including mechanical cues and ligands of G protein-coupled receptors (GPCRs). Through the activation related G proteins and possibly rearrangements of actin cytoskeleton, GPCR signaling can potently modulate the phosphorylation states and activity of YAP and TAZ, two homologous oncogenic transcriptional co-activators, and major effectors of the Hippo pathway. Herein, we summarize the network, regulation, and functions of GPCR-Hippo signaling, and we will also discuss potential anti-cancer therapies targeting GPCR-YAP signaling.

Keywords: G protein-coupled receptor; GPCR; Hippo pathway; YAP/TAZ; anti-cancer therapy; cancer; signal transduction; tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Carcinogenesis / metabolism
  • Carcinogenesis / pathology
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms / metabolism*
  • Protein Serine-Threonine Kinases / metabolism*
  • Receptors, G-Protein-Coupled / metabolism*
  • Signal Transduction*

Substances

  • Receptors, G-Protein-Coupled
  • Protein Serine-Threonine Kinases